Trials / Completed
CompletedNCT05235100
Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02）
Preoperative Intensity-modulated Radiotherapy (IMRT) With Concurrent Apatinib Mesylate for Localised Extremity or Trunk Sarcoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the safety and efficacy of preoperative IMRT and concurrent Apatinib for primary truncal or extremity soft tissue sarcoma; To investigate the Quality of life and extremity function post-combination treatment; To study the mechanism of radio-sensitizing effects of Apatinib for primary truncal or extremity soft tissue sarcoma; To assess the relationship between the MRI imaging, pathological findings and local control.
Conditions
- Sarcoma,Soft Tissue
- Extremity
- Trunk
- Intensity-modulated Radiotherapy
- Targetd Therapy
- Major Wound Complications
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Apatinib Mesylate | Apatinib Mesylate 500mg QD, begin from 2 weeks prior to IMRT, to 1 month after end of IMRT |
Timeline
- Start date
- 2021-09-01
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
- First posted
- 2022-02-10
- Last updated
- 2025-12-11
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05235100. Inclusion in this directory is not an endorsement.